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The factors responsible for abnormal B-cell activation in systemic lupus erythema- 
tosus (SLE) are incompletely understood. This study tested the hypothesis that the ab- 
normal B-cell activation observed in human SLE may be due to an augmented response 
to a helper signal. We demonstrated that non-T cells from 10 of 19 SLE patients in- 
creased IgG production in response to interferon-y (IFN-T) by a mean factor of 20.9 ? 
3.9 over resting levels, while controls stimulated a mean factor of 3.0 2 0.5 (P < 0.005). 
We found no relationship of IFN--y responsiveness to disease activity. Serotyping for 
HLA A, B. C, and D loci suggested that the hyperresponsiveness may be genetically 
linked to HLA-Cw7. We conclude that IFN-7 may contribute to the development and 
perpetuation of SLE in a subset of patients with SLE. n 1988 Academic press. IIK. 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease charac- 
terized by multiple immunologic abnormalities including B lymphocyte hyperac- 
tivity. This hyperactivity is manifested by increased numbers of circulating anti- 
body-forming cells, polyclonal hypergammaglobulinemia, and autoantibody pro- 
duction (l-3). Although factors responsible for the abnormal B-cell activation are 
incompletely understood, potential immunoregulatory defects which might con- 
tribute include T-helper-cell hyperactivity, T-suppressor-cell dysfunction, and 
regulatory abnormalities leading to an increased responsiveness to helper signals 
or a decreased responsiveness to suppressor signals. No consistent abnormalities 
of T-cell function have been demonstrated in human SLE. Several studies sug- 
gested absent or reduced suppressor cell function as a primary factor in the 
pathogenesis of SLE (4-7). However, subsequent reports have described normal 
suppressor T-cell activity (8, 9). 
Polyclonal B-cell hyperactivity has also been demonstrated to be a common 
feature of the SLE-like illness that develops in a variety of genetically predis- 
posed strains of mice. Theofilopoulos, Dixon, and colleagues have demonstrated 
that the New Zealand black/white (NZB/W) and BXSB mouse strains display 
excessive B-cell proliferation and differentiation in response to in vitro lympho- 
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kine challenges and activation signals (IO). Thus, in murine models of SLE, in- 
creased responsiveness of B cells to helper signals may lead to the B-cell hyper- 
activity fundamental to the disease. 
The present study tests the hypothesis that human SLE may be due in part to 
an increased immunoglobulin response to a helper factor. Interferon-y (IFN-v) is 
a T-cell-derived lymphokine that can act as a B-cell differentiation factor (BCDF) 
(11, 12). Furthermore, IFN-y has been shown to accelerate autoimmune disease 
in murine models of SLE (13- 15), and purified recombinant IFN-y is now avail- 
able. For these reasons we selected IFN-y as a model lymphokine for studying 
immunoglobulin responses in SLE. The results demonstrate that a subset of 
human SLE patients have lymphocytes which hyperrespond to IFN-y and which 
may resemble the NZB/W model of SLE. 
PATIENTS AND METHODS 
study sample. SLE subjects were selected from the rheumatology clinic popu- 
lation and in-patient rheumatology service at the University of Michigan. All sub- 
jects fulfilled at least four criteria for the classification of SLE, as defined by the 
American Rheumatism Association (16). Clinical activity was scored according to 
the method of Barada et al. (17), where 0 = complete remission, 1 = mild ac- 
tivity, 2 = moderate activity, and 3 = severe systemic disease. Subjects on more 
than 5 mg per day of prednisone or its equivalent were excluded from study to 
avoid the redistribution effects of corticosteroids on circulating lymphocyte sub- 
populations. Similarly, subjects being treated with cytotoxic agents were ex- 
cluded. The control population consisted of healthy volunteers. 
Isolation of lymphocytes. Peripheral blood mononuclear cells (PBMCs) were 
prepared from heparinized venous blood as previously described (18, 19). T cells 
were depleted by rosetting with sheep erythrocytes treated with 4% 2-aminoethy- 
lisothiouronium bromide hydrobromide (AET, Sigma, St. Louis, MO) as de- 
scribed elsewhere (20). This procedure routinely gives 93% rosette-positive cells 
in the rosetted population and 2% rosette-positive cells in the B-cell-enriched or 
non-T population. Conversely, the number of surface immunoglobulin-positive 
cells in the rosetted, T-enriched population is usually 3%, while the number of 
immunoglobulin-positive cells in the nonrosetting population is approximately 
50%. Where indicated, monocytes were depleted by adherance to 60-mm plastic 
petrie dishes (Nunc) (19). A quantity of IO7 PBMCs was incubated in 5 ml RPM1 
containing 10% fetal bovine serum (FBS) (HyClone, Logan, UT) at 37°C for 1 hr 
and then transferred to a second petrie dish and the incubation was repeated to 
further deplete adherent cells. The B-enriched populations were cultured at 1.25 
x lo5 per well in flat-bottomed 96-well microtiter plates (InterMed-Nunc) in 200 
l.~l of medium containing RPM1 1640 supplemented with 10% FBS, penicillin (100 
IU/ml), streptomycin (100 p.g/ml), and 5 x lO-5 M 2-mercaptoethanol (Sigma). 
The FBS is characterized by the manufacturer (HyClone) and contains less than 
10 rig/ml endotoxin. Purified IFN-y (Genentech, San Francisco, CA) was added 
in concentrations of 103, lo*, and 10 units per well. Cultures were incubated at 
37°C in a 95% air, 5% CO2 humidifed atmosphere. After 4 days, the microtiter 
plates were centrifuged at 4°C for 5 min at 50 R, the culture supernatants were 
INCREASED IMMUNOGLOBULIN RESPONSE TO IFN-y 131 
aspirated, and fresh medium was added. The cultures were incubated an addi- 
tional 6 days and centrifuged, and the cell-free supernatants were harvested. 
Quadruplicate cultures were pooled for assay. 
Assay for immunoglobulin production by enzyme-linked immunoabsorbent 
assays (ELZSA). Total IgG and IgM were quantitated by an ELISA method (21). 
Immulon plates of 96 wells (InterMed-Nunc) were coated with 3.5 kg of goat 
anti-human IgM or 5.0 p,g of goat anti-human IgG (Cappel Laboratores, Inc., 
Westchester, PA) in 100 ~1 of a 0.05 M carbonate buffer, pH 9.6, for 18 hr at 4°C. 
The wells were washed three times with phosphate-buffered saline-0.05% Tween 
20 (J. T. Baker Chemical Co., Phillipsburg, NJ), pH 7.2 (PBS-Tween). To block 
any unbound sites on the plastic, the wells were incubated at room temperature 
for 3 hr with 200 ~1 of 5% bovine serum albumin (BSA) (Sigma) in PBS-Tween. 
The BSA-PBS-Tween solution was removed and 100 t.~l of culture supernatant 
dilutions or appropriate dilutions of standards was added and incubated for 18 hr 
at 4°C. All experimental samples and standards were assayed in quadruplicate. 
The plates were then washed three times with 1% BSA in PBS-Tween. One 
hundred microliters of a 1: 1000 dilution of horseradish peroxidase-conjugated 
goat anti-human immunoglobulin (Sigma) in 1% BSA in PBS-Tween was added. 
The plates were incubated at 4°C for 2 hr and then washed three times with 1% 
BSA in PBS-Tween. One hundred microliters of a developing solution consisting 
of 0.2 M potassium phosphate, 0.003% H,O,. 0.1% Triton X-100, and 10 mg% 
O-dianisidine (Sigma) was added to each well. Color development was arrested 
after 30 min with 100 ~,l of 50% H2S04 and the color was measured at 530 nm 
using a Titertek Multiscan multichannel spectrophotometer. 
Standard curves were generated for each experiment using dilutions of affinity- 
purified IgM myeloma protein (Cappel) and Cohn fraction II human immunoglob- 
ulin (Sigma). Only dilutions of experimental samples that gave optical density 
readings within the linear portion of the standard curves were analyzed. 
Analysis of lymphocyte populations with a jluorescein-activated cell sorter 
(FACS). Cytofluorographic analyses of cell populations were performed by indi- 
rect immunofluorescence with fluorescein isothiocyanate (FIT0conjugated anti- 
bodies to Bl (Coulter Immunology, Hialeah, FL), phycoerythrin-conjugated anti- 
IL2 receptor (Coulter), and FITC-conjugated anti-human Ig (Coulter) using a 
modification of procedures previously described (22). 
Tissue typing. HLA typing for antigens at the A, B, and C loci of the major 
histocompatibility complex was performed by the Tissue Typing Laboratory at 
the University of Michigan, using the microdroplet lymphocytotoxicity method 
on mononuclear cells (23). Typing for HLA-DR antigens was performed on B 
lymphocytes isolated on nylon wool columns (24). Antisera included reagents 
from the 8th International Histocompatibility Workshop (8~) (25). Tissue typing 
was performed on freshly isolated cells or on cells that had been previously 
frozen. In all cases, adequate numbers of B cells were obtained. 
Statistical analysis. P values between the means of groups of data were calcu- 
lated using Student’s t test. Associations between response to IFN-y and HLA- 




Response of c.or~trol and SLE lymphocytc~s to IFN-y. Preliminary experiments 
were performed to optimize the immunoglobulin response to IFN-y. In these 
studies IFN-y was added to cultures of T-depleted cells to avoid the effects of 
IFN-y on helper- and suppressor-T-cell activity (26, 27). Dose-response curves, 
generated for the majority of the patients and controls, demonstrated that most 
subjects responded optimally to 1000 units of IFN-y, although four individuals 
were stimulated optimally with 100 units of IFN-y per well (data not shown). 
Total IgG levels were determined for cells cultured with and without IFN-y to 
assess whether non-T cells from SLE patients respond to IFN-y with increased 
IgG synthesis compared to controls. Resting and activated IgG production is 
plotted for individuals with SLE and controls in Fig. 1. The stimulation index 
(activated/resting IgG synthesis) is reflected by the slopes from resting to stimu- 
lated values. The first group (hyperresponders) has stimulation indexes at least 2 
standard deviations greater than the mean of control values. The second, normal- 
responding, SLE group had elevated resting levels of IgG synthesis, but stimula- 
tion indexes similar to that of controls. In Table 1, the mean concentration of IgG 
produced by the three groups are compared. Subjects with SLE demonstrated an 
increased resting synthesis of IgG. Nineteen patients with SLE had a mean 
resting IgG production of 53 ? 17 rig/ml (mean t SEM). Twelve controls pro- 
duced a mean of 13 t 3 rig/ml IgG at rest. When responses to IFN-y were com- 
pared, 10 patients with SLE had a mean stimulation index of 20.9 I 3.9, while 
controls had a mean stimulation index of 3.0 t 0.5 (P < 0.005). The remaining 9 
patients with SLE had a mean stimulation index of 2.3 ? 0.6. Importantly, the 
unstimulated IgG production by both lupus groups was similar (40 I: 20 vs 66 _+ 
28), indicating that both groups contained comparable numbers of preactivated B 
cells. These data demonstrate that a subset of patients with SLE has non-T lym- 
phocytes which respond to IFN-y with increased synthesis of IgG compared to 
controls, and that B-cell preactivation as measured by unstimulated IgG synthesis 
is not responsible for the difference. 
Two recent reports demonstrate that IFN-1, can act directly on preactivated. 
interleukin-2 receptor (IL-2R)-bearing cells to induce Ig synthesis (28, 29). To test 
whether the hyperresponsive subset contained larger numbers of IL-2R-bearing B 
cells, PBMCs from four hyperresponsive patients, three normal-responding pa- 
tients, and three normal controls were stained with Bl-FITC and phycoerythrin- 
conjugated anti-IL-2R monoclonal antibodies, and then were analyzed by two- 
color flow cytometry. Only one subject in each lupus group had more IL-2R- 
bearing B cells than did the normal controls (data not shown). further indicating 
that B-cell preactivation is not responsible for the observed differences in the 
response to IFN-y. 
As with IgG, SLE patients also demonstrated increased resting synthesis of 
IgM. Mean resting IgM synthesis in 19 SLE patients was 270 ? 137 rig/ml. Mean 
resting IgM synthesis in 12 controls was 131 r 44 rig/ml. In addition, IgM produc- 
tion in response to IFN-?/ was increased in the same subset of 10 lupus patients 
relative to the two other groups, although there was more variation among indi- 








FIG. 1. IgG synthesis of B-enriched lymphocyte preparations at rest and in response to IFN-?I. 1.25 
x 1V B-enriched lymphocytes were cultured in 0.2 ml RPMI, 10% fetal bovine serum, and 5 x 1O-5 
M 2-mercaptoethanol. Cells were cultured with and without IFN-y, 0.5 x lo*-0.5 x 104 units/ml. 
Fresh media was added on Day 4 and supematants were harvested 6 days later. All cultures were 
performed in quadruplicate and supernatants were pooled. Total IgG secreted was measured by an 
ELISA technique. The first group (hyperresponders) have stimulation indexes (activated/resting IgG 
synthesis) at least 2 standard deviations greater than the mean of control values. 
viduals in each group. Table 2 summarizes these results. The hyperresponding 
subset of SLE patients had an IgM stimulation index of 39.4 t 29.1. The re- 
maining 9 SLE patients had an IgM stimulation index of 4.2 + 2.6, similar to the 
control value of 3.7 + 1 S. These data demonstrate that a subset of SLE patients 
responds to IFN-y with increased synthesis of IgM as well as IgG compared to 
controls. 
Comparison of response to IFN-y with number of B lymphocytes. The numbers 
of B lymphocytes in lupus and control PBMCs were compared by flow cytometry 
to assess whether increased numbers of B lymphocytes were responsible for the 
increased immunoglobulin response to IFN-y. B-cell numbers were estimated by 
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TABLE I 
IgG SYNTHESIS OF B-ENRICHED LYMPHOCYTE PREPARATIONS AT REST AND IN RESPONSE TO IFN-y 
IgG concentration in 
culture supernatants (ngimlr’ 
Subjects (H)~ Resting Stimulated Stimulation indexd 
SLE (19) 53 ” 17’ 444 ? 182 12.1 i- 3.0 
Group A (10) 40 -?I 20 694 t 294 20.9 2 3.9’ 
Group B (9) 66 -+ 28 167 t loo 2.3 i_ 0.6 
Control (12) I3 k 3 32 t 7 3.0 2 0.5 
a 1.25 x IO5 B-enriched cells were cultured in 0.2 ml RPMI, 10% fetal bovine serum, and 5 x 10e5 
M 2-mercaptoethanol, with and without IFN--r, 0.5 x 102-0.5 x lo4 u/ml. Fresh media was added on 
Day 4 and supematants were harvested 6 days later. All cultures were performed in quadruplicate, and 
supematants were pooled. Total IgG secreted was measured by an ELISA technique. Results are 
expressed as the mean t SEM of quadruplicate ELISA assays. Maximum IgG resonses are reported. 
b n represents the number of subjects tested. 
c P < 0.005 (Student’s t test) relative to controls. 
d Stimulation index is the ratio of IgG produced by stimulated/resting cells. 
e P < 0.05 (Student’s t test) relative to controls. 
determining the number of cells bearing the surface antigen Bl, as well as the 
number of cells bearing Ig (Table 3). While there was a slight increase in the 
number of cells bearing the Bl antigen in the SLE group, the difference was not 
statistically significant and cannot account for the variations in response to IFN-y 
observed. SLE subjects had a mean of 9.0 -+ 1.3% (+ SEM) Bl-bearing cells, 
while controls had 6.8 +- 0.3%. There was no difference in the number of Bl- 
bearing cells between the SLE subsets. Hyperresponders had an average of 9.2 
t 1.2% B l-positive cells compared to 8.8 + 2.3% in the normal-responding SLE 
group. There was a slight decrease in the number of Ig-bearing cells in the SLE 
group compared to controls, with no differences between SLE subsets. Those 
with an increased response to IFN-y had a mean of 6.7 t 1.2% Ig-bearing cells, 
while normal responders had an average of 6.9 -+ 1.8%. Controls averaged 9.2 k 
1.4% Ig-bearing cells per preparation. 
TABLE 2 
IgM RESPONSETO IFN-~ASEXPRESSEDBYTHE RATIO OFI~M SYNTHESISINSTIMULATEDCELLS 
COMPAREDTORESTINGCELLS 
Subjects (n)O IgM stimulation indexb 
SLE (19) 22.8 ” 15.5 
Group A (10) 39.4 t 29.1 
Group B (9) 4.2 ” 2.6 
Control (8) 3.7 -+ 1.5 
(1 n represents the number of subjects tested. 
b The IgM stimulation index is the ratio of IgM produced by stimulated cells/resting cells. The 
results are expressed as the mean -C SEM. 
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TABLE 3 
PERCENTAGE OF Bl-BEARING CELLS AND Ig-BEARING CELLS IN VENOUS BLOOD OF SLE SUBJECTS 
AND CONTROLS 
Subjects (np 9% B l-bearing cellsb % Ig-bearing cellsb 
SLE (14) 9.0 ‘- 1.3 6.8 k 1.1 
Group A (7) 9.2 2 1.2 6.7 -+ 1.2 
Group B (7) 8.8 k 2.3 6.9 2 1.8 
Normals ( 11) 6.8 5 0.3 9.2 t 1.4 
a n represents the number of subjects. 
b The percentage of Bl- and Ig-bearing cells was determined by flow cytometry. The results are 
expressed as the mean k SEM. 
To determine whether the rosetting step altered the percentage of B cells such 
that non-T cells from the hyperresponding lupus subset had relatively more B 
cells than the other groups, non-T cells from four hyperresponders, three normal- 
responder lupus patients, and three normal controls were stained with Bl-FITC 
and analyzed with the flow cytometer. The percentage of Bl-bearing cells in the 
non-T preparations from the hyperresponding subset was 43.8 + 13.1 (mean + 
SEM) while the normal-responding subset was 47.6 & 14.8, and the normal con- 
trols 51.9 5 7.2. These results demonstrate that the rosetting step did not lead to 
a significant increase in the percentage of B cells in the hyperresponsive subset. 
Comparison of disease activity with response to IFN-7. We recorded an as- 
sessment of disease activity for 16 SLE patients in order to test whether disease 
activity influenced the response to IFN-y. Since subjects taking greater than 5 mg 
of prednisone a day were excluded from study, the study group was biased to- 
ward those with inactive disease, those with milder manifestations for which cor- 
ticosteroids were not indicated, or in two instances, those with active disease 
immediately prior to the administration of high-dose corticosteroids. Subjects 
from the two SLE subsets were being treated similarly with regard to nonster- 
oidal anti-inflammatory and anti-malarial medications. Figure 2 compares disease 
activity and the rise in IgG in response to IFN-y. In the subjects tested in this 
study, there was no correlation between disease activity and response to IFN-y. 
Increased responsiveness to IFN-y was noted in patients with both active and 
inactive disease. In addition, several subjects with very active disease responded 
to IFN-y in the same way as controls. 
Response of purified B cells to ZFN-y. To test whether IFN-y directly stimu- 
lated B cells or required macrophages, adherent cells were depleted from the 
non-T cells by adherence to plastic petrie dishes. The adherence was performed 
twice to assure depletion of monocytes, and then the B cells were cultured with 
IFN-y, using lo5 cells per well. When the IFN-y-induced IgM response by B cells 
from three hyperresponders and three normal responders was studied, no IgM 
synthesis was detected. The IgG response in the same subjects was minimal, with 
one subject from each group producing less than a twofold increase in IgG. The 
other four subjects demonstrated no response (data not shown). Since Ig syn- 
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Normal Controls SLE-Inactive SLE-Active 
FIG. 2. Comparison of disease activity with the 1gG response to IFN-y. Disease activity was scored 
on a 0 to 3 scale according to the method of Barada (17). Disease activity is plotted against the IgG 
response to IFN-7, recorded as the ratio of IgG production in stimulated cells/resting cells (stimula- 
tion index). 
thesis by B cells usually requires T cells and MO, the small amount of IgG syn- 
thesized by these B cells most likely represents preactivated B cells or possibly 
the presence of small numbers of contaminating T cells and MO. These data sug- 
gest that monocytes are required for the B-cell response to IFN-y, but further 
studies will be required to determine whether monocytes, B cells, or other, un- 
identified cells are responsible for the hyperresponsiveness observed. 
HLA-typing in patients with SLE. In order to examine whether the increased 
immunoglobulin response to IFN-y was linked to the major histocompatibility 
complex (MHC), 18 of the lupus patients were serotyped at HLA A, B, C, and D 
loci. A statistically significant increase in HLA-Cw7 was found in the SLE popu- 
lation relative to controls, with a predominance in the group hyperresponsive to 
IFN-y. Twelve of eighteen SLE patients tested (67%) had the Cw7 antigen (P < 
0.01). HLA-Cw7 was predominantly found in the SLE subjects who demon- 
strated an increased response to IFN-7. Eight of nine hyperresponders (89%) 
were positive for Cw7 (P < 0.005, relative risk = 18.9). Four of nine subjects 
(44%) in the normal-responding SLE subset possessed the Cw7 antigen. This per- 
centage is similar to the 30% frequency of the Cw7 antigen in the University of 
Michigan patient population. These results demonstrate that an increased re- 
sponse to IFN-y may be associated with the Cw7 allele. 
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DISCUSSION 
This study demonstrates that lymphocytes from approximately 50% of subjects 
with SLE show an increased responsiveness to a helper signal, IFN-y. In addi- 
tion, we demonstrated an association of HLA Cw7 with SLE, especially in those 
with an increased response to IFN-+y. The increased responsiveness to IFN-JJ was 
observed on cell populations depleted of T lymphocytes, suggesting that the ac- 
tion of IFN-y is on B cells or macrophages. Recent work by three groups of 
investigators has shown that IFN-y can function as a B-cell differentiation factor. 
In these studies, induction of active immunoglobulin secretion occurred via the 
direct interaction of IFN-y and B cells, without involvement of other cell types or 
signals (11, 12). However, in the studies presented here, IFN-y failed to activate 
purified B cells from the hyperresponsive group, suggesting that this is probably 
not the mechanism. In more recent reports, IFN-y and IL-2 were shown to be 
synergistic in inducing B-cell differentiation to antibody-secreting cells (28, 29), 
suggesting that T cells may be involved in the B-cell hyperresponsiveness ob- 
served in this report. However, T cells were depleted from our lymphocyte prep- 
aration, making this mechanism less likely, although a few remaining T cells could 
theoretically support this mechanism. Our observation that depletion of adherent 
cells abrogates the IFN-y-induced antibody response suggests that adherent cells 
are required for the hyperresponsiveness observed in lymphocytes from some 
lupus patients, and may be the cells responsible for the hyperresponsiveness. The 
macrophage may be acting via secreted IL-l, which is involved in B-cell activa- 
tion (30), or the IL-1 may act on a smaller number of remaining T cells to induce 
IL-2 secretion (31). The observation that IFN--y augments specific B-cell re- 
sponses through a Me)-dependent process supports these hypotheses (32). Yet 
another mechanisms for the increased response is suggested by the data of Ro- 
magnani et al. (33), who reported that IFN-y also has B-cell growth-factor ac- 
tivity. These findings would imply that the augmented Ig response in the hyperre- 
sponsive subset may reflect production of a greater number of B cells in vitro, 
resulting in an augmented Ig response. Further studies will be required to deter- 
mine the precise role of M@ and T cells in the augmented Ig response observed. 
Since subjects on greater than 5 mg per day of prednisone or cytotoxic agents 
were excluded from study, the study group was biased toward patients with inac- 
tive disease or with milder manifestations for which corticosteroids were not in- 
dicated. In this population there was no correlation of hyperresponsiveness with 
disease activity. Subjects with both inactive and active disease demonstrated in- 
creased IFN-v responsiveness. Similarly there was no correlation between re- 
sponse to IFN-y and any clinical or laboratory manifestation of SLE. These data 
indicate that hyperresponsiveness is not due to disease activity. 
Other possibilities for the increased IFN-y response include increased numbers 
of B cells in the hyperresponsive SLE subset or increased preactivation of B cells 
in that group. We have demonstrated that the number of B cells is similar in 
PBMC as well as the non-T population from the two SLE subsets and normal 
controls, excluding the possibility that increased numbers of B cells are the 
reason for the observed differences. Possibly the increased responsiveness is due 
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to increased preactivation or “priming” of B cells in viva. However, while both 
groups of SLE patients have increased resting production of immunglobulins in- 
dicating preactivation, there was no difference in the resting immunoglobulin pro- 
duction between the two subsets to indicate greater in vivo activation of the hy- 
perresponsive group. Furthermore, IFN-71 can act as a BCDF on activated but 
not on unstimulated B cells (28. 29). The observation that IFN-?/ did not stimulate 
purified SLE B cells further supports the concept that B-cell preactivation is not 
responsible for the hyperresponsiveness. In addition there was no difference in 
B-cell IL-2R expression between the two lupus groups. By these criteria the state 
of activation of the B cells in each SLE subset is similar and does not account for 
the observed differences in response to IFN-y. 
This study also demonstrates an association of HLA-Cw7 with SLE, in agree- 
ment with an observation recently made by other investigators (34). More specifi- 
cally, an association was detected between the Cw7 allele and SLE subjects who 
demonstrated an increased response to IFN-y. Interestingly, HLA-Cw7 is in 
linkage disequilibrium with both HLA-DR2 and DR-3, serotypes previously asso- 
ciated with SLE (35, 36). Because of the small number of patients studied, addi- 
tional studies need to be performed to confirm the association presented here. If 
further work confirms that HLA-Cw7 is seen in higher frequency in SLE patients 
than is HLA DR-2 or DR-3, it would suggest that this marker may be linked more 
tightly to a gene or genes present in patients with SLE. Recent work by Rashid- 
baigi and colleagues has indicated that the gene for the IFN-y receptor is local- 
ized to chromosome 6 (37). Because the MHC is also present on the sixth chro- 
mosome, the association of Cw7 and an increased response to IFN-y takes on 
increased relevance. 
IFN has been shown to be increased in patients with SLE (38-41). However, 
Preble has identified this IFN as IFN-a, although it was a peculiar acid-labile 
form, like IFN-y (41). Studies by Sibbitt and colleagues have also demonstrated 
that the pathway of IFN-?/ production is normal in patients with SLE and not 
excessively activated (42). These observations suggest that IFN-7 production is 
normal in SLE patients, and the immune defect may lie in the response to normal 
amounts of B-cell differentiation signals. 
In conclusion, this study demonstrates that a subset of patients with SLE has 
lymphocytes which show increased responsiveness to a helper signal, IFN-y. The 
precise mechanism responsible for this hyperactivity is uncertain. It is well 
known that environmental factors such as uv light, viral infections, and certain 
chemicals and drugs can trigger disease activity in SLE patients. Viral infections 
are known to induce large amounts of interferons and other lymphokines, leading 
to a cascade of reactions in humoral and cellular responses. Patients with a pre- 
determined hyperresponsiveness to these regulatory signals could potentially 
overproduce immunoglobulins, autoantibodies. and immune complexes, leading 
to the lupus state. Given the observations with IFN-y, it is possible that this 
family of immunoregulatory molecules may contribute to the development and 
perpetuation of SLE. Further work on the mechanism of action of IFN-)I on SLE 
lymphocytes may lead to an increased understanding of the pathogenesis of this 
disease. 
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